文献速递角膜与眼表疾病

微生物性角膜炎视力结局相关因素:多中心前瞻性队列研究

Factors Associated with Vision Outcomes in Microbial Keratitis: A Multisite Prospective Cohort Study.
PubMed 文献 · Ophthalmology · 2025-02-08

该多中心前瞻性队列研究纳入美国与印度479例微生物性角膜炎患者,随访90天,发现初始视力较差、就诊延迟和基质浸润面积较大与90天最佳矫正视力较差相关,其他相关因素两国不同。

要点

  • 初始视力较差、就诊延迟和基质浸润面积较大与90天视力较差相关。
  • 美国队列中未使用接触镜和较大细菌或真菌浸润面积与视力较差相关。
  • 印度队列中糖尿病、前房积脓和无近期眼外伤与视力较差相关。

核心结论

  • 初始视力、就诊延迟时间和浸润面积较大与90天最佳矫正视力较差相关,其他因素两国各异。
  • 需要建立减少诊疗延迟和支持就医的系统,以帮助临床医生并改善视力结局。

研究设计与样本

  • 多中心前瞻性队列研究,2020年7月23日至2024年5月1日从美国和印度招募微生物性角膜炎患者并随访90天。
  • 纳入≥15岁、基质浸润面积>2 mm²、无既往角膜手术或角膜粘合、无即将角膜穿孔或角膜移植、无无光感视力、非妊娠、非监禁的微生物性角膜炎患者。
  • 收集社会人口学、病史、症状、临床指标和初始及90天最佳矫正视力(BCVA,以最小分辨角对数[logMAR]单位表示),90天前愈合者BCVA沿用。
  • 采用按中心分层的多变量线性回归模型分析与90天BCVA的相关性。
  • 479例参与者纳入分析,排除31例及无90天BCVA者52例。

主要发现

  • 美国参与者90天平均BCVA为1.36±1.40 logMAR,印度为0.70±0.99 logMAR(P<0.0001)。
  • 美国队列:90天BCVA较差与初始BCVA较差(初始BCVA每增加0.1 logMAR单位,β=0.05 logMAR;P<0.0001)、就诊时间较长(β=0.01/天;P<0.0001)、未使用接触镜(β=0.46;P=0.0131)和较大基质浸润面积(细菌:每1 mm² β=0.02[P=0.0082];真菌:每1 mm² β=0.10[P=0.0002];交互作用P=0.0017)相关。
  • 印度队列:90天BCVA较差与初始BCVA较差(β=0.04 logMAR;P<0.0001)、就诊延迟较长(β=0.03/天;P=0.0004)、糖尿病(β=0.41;P=0.0019)、前房积脓(β=0.27;P=0.0083)、无近期眼外伤(β=0.21;P=0.0370)和较大基质浸润面积(真菌:每1 mm² β=0.03[P<0.0001];细菌:β不显著[P=0.07];交互作用P=0.0001)相关。

临床怎么用

  • 原文结论指出需要建立减少诊疗延迟和支持就医的系统,以帮助临床医生并改善视力结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate factors associated with 90-day vision in patients with microbial keratitis (MK). DESIGN: Multicenter prospective cohort study recruited patients with MK from the United States and India from July 23, 2020, through May 1, 2024, and followed them for 90 days. PARTICIPANTS: Individuals ≥ 15 years of age with MK of > 2 mm2 in stromal infiltrate area without prior corneal surgery or gluing, impending corneal perforation or keratoplasty, no light perception vision, current pregnancy, or incarceration. METHODS: Data on sociodemographics, history, symptoms, clinical measures, and best-corrected visual acuity (BCVA) (as logarithm of the minimum angle of resolution [logMAR] units) at initial and 90-day visits were gathered, with BCVA carried forward for those healed before 90 days. Features were summarized overall and by site. Site-stratified multivariable linear regression models were investigated for associations with 90-day BCVA. MAIN OUTCOME MEASURES: Ninety-day logMAR BCVA. RESULTS: Of 479 participants analyzed, after exclusions (n = 31) and participants without a 90-day BCVA (n = 52), participants had an average 90-day BCVA of 1.36 ± 1.40 logMAR in the United States (US) and 0.70 ± 0.99 logMAR in India (P < 0.0001). For the US, worse 90-day BCVA was associated with worse presenting BCVA (β = 0.05-logMAR per 0.1-logMAR unit increase in presenting BCVA; P < 0.0001), longer time until presentation (β = 0.01 per day; P < 0.0001), no contact lens use (β = 0.46; P = 0.0131), and larger stromal infiltrate area (bacterial: β = 0.02 per 1-mm2 [P = 0.0082]; fungal: β = 0.10 per 1-mm2 increase in area [P = 0.0002]; P = 0.0017 for interaction). For the India, worse 90-day BCVA was associated with worse presenting BCVA (β = 0.04 logMAR; P < 0.0001), longer delays to presentation (β = 0.03 per day; P = 0.0004), diabetes mellitus (β = 0.41; P = 0.0019), hypopyon (β = 0.27; P = 0.0083), no recent ocular trauma (β = 0.21; P = 0.0370), and larger stromal infiltrate area (fungal: β = 0.03 per 1-mm2 [P < 0.0001]; bacterial: nonsignificant β [P = 0.07]; P = 0.0001 for interaction). CONCLUSIONS: Initial vision, longer time until presentation, and larger infiltrate size conferred risk for worse 90-day BCVA, whereas other factors were unique. Systems to mitigate care delays and to support access care are needed would support clinicians and improve vision outcomes. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Woodward MA, Vogt EL, Niziol LM, et al. Factors Associated with Vision Outcomes in Microbial Keratitis: A Multisite Prospective Cohort Study. Ophthalmology. 2025. PMID: 39929390. doi:10.1016/j.ophtha.2025.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。